Key clinical point: Adding a recombinant Flt3 ligand, CDX-301, to a dendritic cell-targeted vaccine, CDX-1401, improved immune response in patients with malignant melanoma.
Major finding: T-cell responses were detected in 76% of patients who were pretreated with CDX-301 and in 33% of patients who were not (P < .0011).
Study details: A randomized, phase 2 study of 60 patients with resected stage IIb-IV melanoma.
Disclosures: The study was supported by grant funding from the National Cancer Institute. Some authors reported financial affiliations with Celldex Therapeutics, NanoString Technologies, and Oncovir.
Bhardwaj N et al. Nat Cancer. 2020 Nov 16. doi: 10.1038/s43018-020-00143-y.